The stock of Aptose Biosciences Inc (APTO) has gone down by -13.91% for the week, with a -18.13% drop in the past month and a -18.94% drop in the past quarter. The volatility ratio for the week is 8.76%, and the volatility levels for the past 30 days are 7.22% for APTO. The simple moving average for the past 20 days is -13.51% for APTO’s stock, with a -63.71% simple moving average for the past 200 days.
Is It Worth Investing in Aptose Biosciences Inc (NASDAQ: APTO) Right Now?
Additionally, the 36-month beta value for APTO is 1.20. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APTO is 16.19M and currently, short sellers hold a 0.76% ratio of that float. The average trading volume of APTO on November 20, 2024 was 539.43K shares.
APTO) stock’s latest price update
Aptose Biosciences Inc (NASDAQ: APTO)’s stock price has dropped by -8.83 in relation to previous closing price of 0.36. Nevertheless, the company has seen a loss of -13.91% in its stock price over the last five trading days. globenewswire.com reported 2024-11-20 that TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations Study execution update is expected during ASH 2024 SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced initiation of the TUSCANY study, tuspetinib (TUS) in combination therapy with azacitidine (AZA) and venetoclax (VEN) as a frontline triplet combination therapy for patients newly diagnosed with acute myeloid leukemia, or AML. The trial is being conducted at multiple U.S. clinical sites.
Analysts’ Opinion of APTO
Many brokerage firms have already submitted their reports for APTO stocks, with Cantor Fitzgerald repeating the rating for APTO by listing it as a “Overweight.” The predicted price for APTO in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on October 19, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see APTO reach a price target of $12. The rating they have provided for APTO stocks is “Buy” according to the report published on September 22nd, 2020.
Maxim Group gave a rating of “Buy” to APTO, setting the target price at $16 in the report published on February 20th of the previous year.
APTO Trading at -14.37% from the 50-Day Moving Average
After a stumble in the market that brought APTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.74% of loss for the given period.
Volatility was left at 7.22%, however, over the last 30 days, the volatility rate increased by 8.76%, as shares sank -16.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.76% lower at present.
During the last 5 trading sessions, APTO fell by -13.43%, which changed the moving average for the period of 200-days by -84.89% in comparison to the 20-day moving average, which settled at $0.3787. In addition, Aptose Biosciences Inc saw -87.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APTO
Current profitability levels for the company are sitting at:
- -41.45 for the present operating margin
- 0.52 for the gross margin
The net margin for Aptose Biosciences Inc stands at -50.67. The total capital return value is set at -25.21. Equity return is now at value -694.13, with -225.12 for asset returns.
Based on Aptose Biosciences Inc (APTO), the company’s capital structure generated -0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -37.5. The debt to equity ratio resting at -0.08. The interest coverage ratio of the stock is -53.58.
Currently, EBITDA for the company is -52.27 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of -1.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
In conclusion, Aptose Biosciences Inc (APTO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
